The Next White (NEW) detector

[EN] Conceived to host 5 kg of xenón at a pressure of 15 bar in the ¿ducial volume,the NEXTWhite (NEW)apparatus is currently the largest high pressure xenon gas TPC using electroluminescent ampli¿cation in the world. It is also a 1:2 scale model of the NEXT-100 detector scheduled to start searching for ßß0¿ decays in 136Xe in 2019. Both detectors measure the energy of the event using a plane of photomultipliers located behind a transparent cathode. They can also reconstruct the trajectories of charged tracks in the dense gas of the TPC with the help of a plane of silicon photomultipliers located behind the anode. A sophisticated gas system, common to both detectors, allows the high gas purity needed to guarantee a long electron lifetime. NEXT-White has been operating since October 2017 at the Canfranc Underground Laboratory (LSC), in Spain. This paper describes the detector and associated infrastructures.The NEXT Collaboration acknowledges support from the following agencies and institutions: the European Research Council (ERC) under the Advanced Grant 339787-NEXT; the European Union's Framework Programme for Research and Innovation Horizon 2020 (2014-2020) under the Marie Sklodowska-Curie Grant Agreements No. 674896, 690575 and 740055; the Ministerio de Economia y Competitividad of Spain under grants FIS2014-53371-C04, the Severo Ochoa Program SEV-2014-0398 and the Maria de Maetzu Program MDM-2016-0692; the GVA of Spain under grants PROMETEO/2016/120 and SEJI/2017/011; the Portuguese FCT and FEDER through the program COMPETE, projects PTDC/FIS-NUC/2525/2014 and UID/FIS/04559/2013; the U.S. Department of Energy under contract numbers DE-AC02-07CH11359 (Fermi National Accelerator Laboratory), DE-FG02-13ER42020 (Texas A&M), DE-SC0017721 (University of Texas at Arlington), and DE-AC02-06CH11357 (Argonne National Laboratory); and the University of Texas at Arlington. We also warmly acknowledge the Laboratorio Nazionale di Gran Sasso (LNGS) and the Dark Side collaboration for their help with TPB coating of various parts of the NEXT-White TPC. Finally, we are grateful to the Laboratorio Subterraneo de Canfranc for hosting and supporting the NEXT experiment.Monrabal, F.; Gomez-Cadenas, JJ.; Toledo Alarcón, JF.; Laing, A.; Álvarez-Puerta, V.; Benlloch-Rodriguez, JM.; Carcel, S.... (2018). The Next White (NEW) detector. Journal of Instrumentation. 13:1-35. https://doi.org/10.1088/1748-0221/13/12/P12010S13513Nygren, D. (2009). High-pressure xenon gas electroluminescent TPC for 0-ν ββ-decay search. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 603(3), 337-348. doi:10.1016/j.nima.2009.01.222Gómez Cadenas, J. J., Álvarez, V., Borges, F. I. G., Cárcel, S., Castel, J., Cebrián, S., … Dias, T. H. V. T. (2014). Present Status and Future Perspectives of the NEXT Experiment. Advances in High Energy Physics, 2014, 1-22. doi:10.1155/2014/907067Martín-Albo, J., Muñoz Vidal, J., Ferrario, P., Nebot-Guinot, M., Gómez-Cadenas, J. J., … Cárcel, S. (2016). Sensitivity of NEXT-100 to neutrinoless double beta decay. Journal of High Energy Physics, 2016(5). doi:10.1007/jhep05(2016)159Álvarez, V., Borges, F. I. G., Cárcel, S., Castel, J., Cebrián, S., Cervera, A., … Díaz, J. (2013). Initial results of NEXT-DEMO, a large-scale prototype of the NEXT-100 experiment. Journal of Instrumentation, 8(04), P04002-P04002. doi:10.1088/1748-0221/8/04/p04002Álvarez, V., Borges, F. I. G., Cárcel, S., Castel, J., Cebrián, S., Cervera, A., … Díaz, J. (2013). Operation and first results of the NEXT-DEMO prototype using a silicon photomultiplier tracking array. Journal of Instrumentation, 8(09), P09011-P09011. doi:10.1088/1748-0221/8/09/p09011Álvarez, V., Borges, F. I. G. M., Cárcel, S., Castel, J., Cebrián, S., Cervera, A., … Díaz, J. (2013). Near-intrinsic energy resolution for 30–662keV gamma rays in a high pressure xenon electroluminescent TPC. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 708, 101-114. doi:10.1016/j.nima.2012.12.123Ferrario, P., Laing, A., López-March, N., Gómez-Cadenas, J. J., Álvarez, V., … Cebrián, S. (2016). First proof of topological signature in the high pressure xenon gas TPC with electroluminescence amplification for the NEXT experiment. Journal of High Energy Physics, 2016(1). doi:10.1007/jhep01(2016)104López-March, N. (2017). Sensitivity of the NEXT-100 detector to neutrinoless double beta decay. Journal of Physics: Conference Series, 888, 012243. doi:10.1088/1742-6596/888/1/012243Álvarez, V., Borges, F. I. G., Cárcel, S., Cebrián, S., Cervera, A., Conde, C. A. N., … Esteve, R. (2013). Ionization and scintillation response of high-pressure xenon gas to alpha particles. Journal of Instrumentation, 8(05), P05025-P05025. doi:10.1088/1748-0221/8/05/p05025Gehman, V. M., Seibert, S. R., Rielage, K., Hime, A., Sun, Y., Mei, D.-M., … Moore, D. (2011). Fluorescence efficiency and visible re-emission spectrum of tetraphenyl butadiene films at extreme ultraviolet wavelengths. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 654(1), 116-121. doi:10.1016/j.nima.2011.06.088Sanguino, P., Balau, F., Botelho do Rego, A. M., Pereira, A., & Chepel, V. (2016). Stability of tetraphenyl butadiene thin films in liquid xenon. Thin Solid Films, 600, 65-70. doi:10.1016/j.tsf.2016.01.006Silva, C., Pinto da Cunha, J., Pereira, A., Chepel, V., Lopes, M. I., Solovov, V., & Neves, F. (2010). Reflectance of polytetrafluoroethylene for xenon scintillation light. Journal of Applied Physics, 107(6), 064902. doi:10.1063/1.3318681Christophorou, L. G. (1988). Insulating gases. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 268(2-3), 424-433. doi:10.1016/0168-9002(88)90550-5Vijh, A. K. (1985). Relative electric strengths and polarizabilities of gaseous dielectrics. Materials Chemistry and Physics, 12(3), 287-296. doi:10.1016/0254-0584(85)90098-7Rebel, B., Hall, C., Bernard, E., Faham, C. H., Ito, T. M., Lundberg, B., … Wang, H. (2014). High voltage in noble liquids for high energy physics. Journal of Instrumentation, 9(08), T08004-T08004. doi:10.1088/1748-0221/9/08/t08004Cebrián, S., Pérez, J., Bandac, I., Labarga, L., Álvarez, V., Azevedo, C. D. R., … Cárcel, S. (2017). Radiopurity assessment of the energy readout for the NEXT double beta decay experiment. Journal of Instrumentation, 12(08), T08003-T08003. doi:10.1088/1748-0221/12/08/t08003Lung, K., Arisaka, K., Bargetzi, A., Beltrame, P., Cahill, A., Genma, T., … Yoshizawa, Y. (2012). Characterization of the Hamamatsu R11410-10 3-in. photomultiplier tube for liquid xenon dark matter direct detection experiments. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 696, 32-39. doi:10.1016/j.nima.2012.08.052Rodríguez, J., Toledo, J., Esteve, R., Lorca, D., & Monrabal, F. (2015). The front-end electronics for the 1.8-kchannel SiPM tracking plane in the NEW detector. Journal of Instrumentation, 10(01), C01025-C01025. doi:10.1088/1748-0221/10/01/c01025Carena, F., Carena, W., Chapeland, S., Chibante Barroso, V., Costa, F., Dénes, E., … von Haller, B. (2014). The ALICE data acquisition system. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 741, 130-162. doi:10.1016/j.nima.2013.12.015Martoiu, S., Muller, H., Tarazona, A., & Toledo, J. (2013). Development of the scalable readout system for micro-pattern gas detectors and other applications. Journal of Instrumentation, 8(03), C03015-C03015. doi:10.1088/1748-0221/8/03/c03015Toledo, J., Muller, H., Esteve, R., Monzó, J. M., Tarazona, A., & Martoiu, S. (2011). The Front-End Concentrator card for the RD51 Scalable Readout System. Journal of Instrumentation, 6(11), C11028-C11028. doi:10.1088/1748-0221/6/11/c11028Esteve, R., Toledo, J., Rodríguez, J., Querol, M., & Álvarez, V. (2016). Readout and data acquisition in the NEXT-NEW Detector based on SRS-ATCA. Journal of Instrumentation, 11(01), C01008-C01008. doi:10.1088/1748-0221/11/01/c01008Esteve, R., Toledo, J., Monrabal, F., Lorca, D., Serra, L., Marí, A., … Mora, F. (2012). The trigger system in the NEXT-DEMO detector. Journal of Instrumentation, 7(12), C12001-C12001. doi:10.1088/1748-0221/7/12/c12001Herzenberg, A. (1969). Attachment of Slow Electrons to Oxygen Molecules. The Journal of Chemical Physics, 51(11), 4942-4950. doi:10.1063/1.1671887Huk, M., Igo-Kemenes, P., & Wagner, A. (1988). Electron attachment to oxygen, water, and methanol, in various drift chamber gas mixtures. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 267(1), 107-119. doi:10.1016/0168-9002(88)90635-3Novella, P., Palmeiro, B., Simón, A., Sorel, M., Adams, C., … Zuzel, G. (2018). Measurement of radon-induced backgrounds in the NEXT double beta decay experiment. Journal of High Energy Physics, 2018(10). doi:10.1007/jhep10(2018)112Saldanha, R., Grandi, L., Guardincerri, Y., & Wester, T. (2017). Model independent approach to the single photoelectron calibration of photomultiplier tubes. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 863, 35-46. doi:10.1016/j.nima.2017.02.086Simón, A., Felkai, R., Martínez-Lema, G., Monrabal, F., González-Díaz, D., Sorel, M., … Álvarez, V. (2018). Electron drift properties in high pressure gaseous xenon. Journal of Instrumentation, 13(07), P07013-P07013. doi:10.1088/1748-0221/13/07/p07013Martínez-Lema, G., Morata, J. A. H., Palmeiro, B., Botas, A., Ferrario, P., Monrabal, F., … Para, A. (2018). Calibration of the NEXT-White detector using 83mKr decays. Journal of Instrumentation, 13(10), P10014-P10014. doi:10.1088/1748-0221/13/10/p1001

Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells.

The CD11b/CD18 integrin (complement receptor 3, CR3) is a surface receptor on monocytes, neutrophils, macrophages and dendritic cells that plays a crucial role in several immunological processes including leukocyte extravasation and phagocytosis. The minor allele of a non-synonymous CR3 polymorphism (rs1143679, conversation of arginine to histidine at position 77: R77H) represents one of the strongest genetic risk factor in human systemic lupus erythematosus, with heterozygosity (77R/H) being the most common disease associated genotype. Homozygosity for the 77H allele has been reported to reduce adhesion and phagocytosis in human monocytes and monocyte-derived macrophages, respectively, without affecting surface expression of CD11b. Herein we comprehensively assessed the influence of R77H on different CR3-mediated activities in monocytes, neutrophils, macrophages and dendritic cells. R77H did not alter surface expression of CD11b including its active form in any of these cell types. Using two different iC3b-coated targets we found that the uptake by heterozygous 77R/H macrophages, monocytes and neutrophils was significantly reduced compared to 77R/R cells. Allele-specific transduced immortalized macrophage cell lines demonstrated that the minor allele, 77H, was responsible for the impaired phagocytosis. R77H did not affect neutrophil adhesion, neutrophil transmigration in vivo or Toll-like receptor 7/8-mediated cytokine release by monocytes or dendritic cells with or without CR3 pre-engagement by iC3b-coated targets. Our findings demonstrate that the reduction in CR3-mediated phagocytosis associated with the 77H CD11b variant is not macrophage-restricted but demonstrable in other CR3-expressing professional phagocytic cells. The association between 77H and susceptibility to systemic lupus erythematosus most likely relates to impaired waste disposal, a key component of lupus pathogenesis

Characterizing the scent and chemical composition of Panthera leo marking fluid using solid-phase microextraction and multidimensional gas chromatography–mass spectrometry-olfactometry

Lions (Panthera leo) use chemical signaling to indicate health, reproductive status, and territorial ownership. To date, no study has reported on both scent and composition of marking fluid (MF) from P. leo. The objectives of this study were to: 1) develop a novel method for simultaneous chemical and scent identification of lion MF in its totality (urine + MF), 2) identify characteristic odorants responsible for the overall scent of MF as perceived by human panelists, and 3) compare the existing library of known odorous compounds characterized as eliciting behaviors in animals in order to understand potential functionality in lion behavior. Solid-phase microextraction and simultaneous chemical-sensory analyses with multidimensional gas-chromatography-mass spectrometry-olfactometry improved separating, isolating, and identifying mixed (MF, urine) compounds versus solvent-based extraction and chemical analyses. 2,5-Dimethylpyrazine, 4-methylphenol, and 3-methylcyclopentanone were isolated and identified as the compounds responsible for the characteristic odor of lion MF. Twenty-eight volatile organic compounds (VOCs) emitted from MF were identified, adding a new list of compounds previously unidentified in lion urine. New chemicals were identified in nine compound groups: ketones, aldehydes, amines, alcohols, aromatics, sulfur-containing compounds, phenyls, phenols, and volatile fatty acids. Twenty-three VOCs are known semiochemicals that are implicated in attraction, reproduction, and alarm-signaling behaviors in other species

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

EFFECT OF SALINITY ON GROWTH OF TETRASPORELINGS OF GRACILARIA-VERRUCOSA RHODOPHYTA GIGARTINALES

Volume: 41Start Page: 119End Page: 12